Top

Published in:

Open Access 01-12-2018 | Research article

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Authors: Chi Zhang, Fan Zhang, Guanzhao Liang, Xianshang Zeng, Weiguang Yu, Zhidao Jiang, Jie Ma, Mingdong Zhao, Min Xiong, Keke Gui, Fenglai Yuan, Weiping Ji

Published in: BMC Musculoskeletal Disorders | Issue 1/2018

Abstract

Background

The purpose of this study was to evaluate the efficacy of denosumab or zoledronic acid (ZA) using symptomatic skeletal events (SSEs) as the primary endpoint in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer.

Methods

Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer receiving subcutaneous denosumab 120 mg Q4W, or intravenous ZA 4 mg Q4W until the primary analysis cut-off date were retrospectively analysed in the Hong Kong Practice-Based Cancer Research Center(HKCRC) from March 2011 to March 2013. The time to first on-study SSE that was assessed either clinically or through routine radiographic scans was the primary endpoint.

Results

242 patients received denosumab or ZA treatment (n = 120, mean age of 64.9 years (SD 3.01) and n = 122, 65.4 years (3.44), respectively). The median times to first on-study SSE were 14.7 months (12.9–45.6) and 11.7 months (9.9–45.6) for denosumab and ZA, respectively (hazard ratio, HR 0.44, 95% CI 0.71–2.95; p = 0·0002). Compared with the ZA group, denosumab-treated patients had a significantly delayed time to first SSE (HR 0.65 [95% CI 0.29–1.45], p < 0.0001). An increased incidence of SSE was found in the 16-month follow-up with rates of 2.1 and 10.7% for denosumab and ZA, respectively (P = 0.033). The difference persisted with time with rates of 8.3 and 17.2% at the final follow-up, respectively (P < 0.05).

Conclusion

In postmenopausal women aged ≥60 years with oestrogen-receptor-positive advanced breast cancer, denosumab significantly reduced the risk of developing SSEs compared with ZA. The findings of this pilot trial justify a larger study to determine whether the result is more generally applicable to a broader population.

Gnant M, Pfeiler G, Dubsky PC, Hubalek M, Greil R, Jakesz R, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386(9992):433–43. https://doi.org/10.1016/s0140-6736(15)60995-3.CrossRefPubMed

Brown JP, Dempster DW, Ding BY, Dent-Acosta R, San Martin J, Grauer A, et al. Bone remodeling in postmenopausal women who discontinued Denosumab treatment: off-treatment biopsy study. J Bone Miner Res. 2011;26(11):2737–44. https://doi.org/10.1002/jbmr.448.CrossRefPubMed

Cappetta A, Spano L, Evangelista L, Zovato S, Opocher G, Pastorelli D. Impressive response to denosumab in a patient with bone metastatic adenocarcinoma of the stomach after 2 years of zoledronic acid. Anti-Cancer Drugs. 2015;26(2):232–5. https://doi.org/10.1097/cad.0000000000000169.CrossRefPubMed

Husnoo N, Abbas S. Management of Aromatase Inhibitor-Induced Bone Loss in breast Cancer patients. Br J Surg. 2016;103:134–5.

Brown JP, Reid IR, Wagman RB, Kendler D, Miller PD, Jensen JEB, et al. Effects of up to 5 years of Denosumab treatment on bone histology and Histomorphometry: the FREEDOM study extension. J Bone Miner Res. 2014;29(9):2051–6. https://doi.org/10.1002/jbmr.2236.CrossRefPubMed

Brown JP, Roux C, Ho PR, Bolognese MA, Hall J, Bone HG, et al. Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporos Int. 2014;25(7):1953–61. https://doi.org/10.1007/s00198-014-2692-7.CrossRefPubMed

Campbell-Baird C, Harrelson S, Frey G, Balakumaran A. Clinical efficacy of denosumab versus bisphosphonates for the prevention of bone complications: implications for nursing. Support Care Cancer. 2015;23(12):3625–32. https://doi.org/10.1007/s00520-015-2887-2.CrossRefPubMed

Body JJ, Bone HG, De Boer RH, Stopeck A, Van Poznak C, Damiao R, et al. Hypocalcaemia in patients with metastatic bone disease treated with denosumab. Eur J Cancer. 2015;51(13):1812–21. https://doi.org/10.1016/j.ejca.2015.05.016.CrossRefPubMed

Lewiecki EM. Denosumab update. Curr Opin Rheumatol. 2009;21(4):369–73. https://doi.org/10.1097/BOR.0b013e32832ca41c.CrossRefPubMed

10.

Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398–405. https://doi.org/10.1093/annonc/mds277.CrossRefPubMed

11.

Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997–1006. https://doi.org/10.1016/s1470-2045(14)70302-x.CrossRefPubMed

12.

Coleman R, Hadji P. Denosumab and fracture risk in women with breast cancer. Lancet. 2015;386(9992):409–10. https://doi.org/10.1016/s0140-6736(15)61032-7.CrossRefPubMed

13.

Costa AG, Bilezikian JP. How long to treat with Denosumab. Curr Osteoporos Rep. 2015;13(6):415–20. https://doi.org/10.1007/s11914-015-0295-7.CrossRefPubMed

14.

Araki K, Ito Y, Takahashi S. Re: superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of three pivotal, randomised, phase 3 trials. Eur J Cancer. 2013;49(9):2264–5. https://doi.org/10.1016/j.ejca.2013.02.036.CrossRefPubMed

15.

Coleman RE, Rathbone E, Brown JE. Management of cancer treatment-induced bone loss. Nat Rev Rheumatol. 2013;9(6):365–74. https://doi.org/10.1038/nrrheum.2013.36.CrossRefPubMed

16.

Boskovic L, Gasparic M, Petkovic M, Gugic D, Lovasic IB, Soldic Z, et al. Bone health and adherence to vitamin D and calcium therapy in early breast cancer patients on endocrine therapy with aromatase inhibitors. Breast. 2017;31:16–9. https://doi.org/10.1016/j.breast.2016.10.018.CrossRefPubMed

17.

Anastasilakis AD, Makras P. Multiple clinical vertebral fractures following denosumab discontinuation. Osteoporos Int. 2016;27(5):1929–30. https://doi.org/10.1007/s00198-015-3459-5.CrossRefPubMed

18.

Smith MR, Coleman RE, Klotz L, Pittman K, Milecki P, Ng S, et al. Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events. Ann Oncol. 2015;26(2):368–74. https://doi.org/10.1093/annonc/mdu519.CrossRefPubMed

19.

Farooki A, Fornier M. Denosumab and fracture risk in women with breast cancer. Lancet. 2015;386(10008):2056–7.CrossRef

20.

Wilcken N, Lee CI. In postmenopausal women with breast cancer treated with aromatase inhibitors, denosumab reduced fractures. Ann Intern Med. 2015;163(6). doi:https://doi.org/10.7326/acpjc-2015-163-6-011.

21.

Abdel-Rahman O. Denosumab versus zoledronic acid to prevent aromatase inhibitors-associated fractures in postmenopausal early breast cancer; a mixed treatment meta-analysis. Expert Rev Anticancer Ther. 2016;16(8):885–91. https://doi.org/10.1080/14737140.2016.1192466.CrossRefPubMed

22.

Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M. Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases. J Clin Oncol. 2011;29(27).

23.

Ekholm M, Bendahl P-O, Ferno M, Nordenskjold B, Stal O, Ryden L. Two Years of Adjuvant Tamoxifen Provides a Survival Benefit Compared With No Systemic Treatment in Premenopausal Patients With Primary Breast Cancer: Long-Term Follow-Up (> 25 years) of the Phase III SBII:2pre Trial. J Clin Oncol. 2016;34(19):2232−+. doi:https://doi.org/10.1200/jco.2015.65.6272.

24.

Nakamura T, Matsumoto T, Sugimoto T, Hosoi T, Miki T, Gorai I, et al. Clinical trials express: fracture risk reduction with Denosumab in Japanese postmenopausal women and men with osteoporosis: Denosumab fracture intervention randomized placebo controlled trial (DIRECT). J Clin Endocrinol Metab. 2014;99(7):2599–607. https://doi.org/10.1210/jc.2013-4175.CrossRefPubMedPubMedCentral

25.

Sugimoto T, Matsumoto T, Hosoi T, Miki T, Gorai I, Yoshikawa H, et al. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab fracture intervention randomized placebo controlled trial (DIRECT). Osteoporos Int. 2015;26(2):765–74. https://doi.org/10.1007/s00198-014-2964-2.CrossRefPubMed

26.

Xie JP, Diener M, Sorg R, Wu EQ, Namjoshi M. Cost-effectiveness of Denosumab compared with Zoledronic acid in patients with breast Cancer and bone metastases. Clin Breast Cancer. 2012;12(4):247–58. https://doi.org/10.1016/j.clbc.2012.04.001.CrossRefPubMed

27.

Lipton A. Denosumab in breast Cancer. Curr Oncol Rep. 2011;13(1):1–4. https://doi.org/10.1007/s11912-010-0135-y.CrossRefPubMed

28.

Martin M, Bell R, Bourgeois H, Brufsky A, Diel I, Eniu A, et al. Bone-related complications and quality of life in advanced breast Cancer: results from a randomized phase III trial of Denosumab versus Zoledronic acid. Clin Cancer Res. 2012;18(17):4841–9. https://doi.org/10.1158/1078-0432.ccr-11-3310.CrossRefPubMed

29.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Fan M, et al. Effect of denosumab on bone mineral density in women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: subgroup analyses of a phase 3 study. Breast Cancer Res Treat. 2009;118(1):81–7. https://doi.org/10.1007/s10549-009-0352-y.CrossRefPubMed

30.

Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P. Comparative effect of Zoledronic acid versus Denosumab on serum Sclerostin and Dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab. 2013;98(8):3206–12. https://doi.org/10.1210/jc.2013-1402.CrossRefPubMed

Title: Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years
Authors: Chi Zhang
Fan Zhang
Guanzhao Liang
Xianshang Zeng
Weiguang Yu
Zhidao Jiang
Jie Ma
Mingdong Zhao
Min Xiong
Keke Gui
Fenglai Yuan
Weiping Ji
Publication date: 01-12-2018
Publisher: BioMed Central
Published in: BMC Musculoskeletal Disorders / Issue 1/2018
Electronic ISSN: 1471-2474
DOI: https://doi.org/10.1186/s12891-018-2338-6

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Denosumab versus zoledronic acid for preventing symptomatic skeletal events in Asian postmenopausal women with oestrogen-receptor-positive advanced breast cancer: an outcome analyses with a mean follow-up of 3 years

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2018

Self-reported functional recovery after reconstruction versus repair in acute anterior cruciate ligament rupture (ROTOR): a randomized controlled clinical trial

Single cut distal femoral osteotomy for correction of femoral torsion and valgus malformity in patellofemoral malalignment - proof of application of new trigonometrical calculations and 3D-printed cutting guides

Validation of the Polish version of the Western Ontario Rotator Cuff Index in patients following arthroscopic rotator cuff repair

Serial changes in the head-shaft angle of proximal humeral fractures treated by placing locking plates: a retrospective study

Intra- and interobserver reliability of glenoid fracture classifications by Ideberg, Euler and AO

Prevalence of and characteristics associated with insomnia and obstructive sleep apnea among veterans with knee and hip osteoarthritis